Thursday, August 4, 2022 Daily Archives

Thermo Fisher shells out $76m to expand NY cell culture media site

by

The $76 million investment will increase the cell culture media manufacturing site in Grand Island, New York, which Thermo says is critical to produce vaccines and biologic therapies. The $76 million funding is part of a long-term $650 million investment the firm announced last March and Thermo Fisher Scientific said it aims to meet global demand for cell culture media by expanding its dry powder media manufacturing plant in Grand Island. “Our expanded Grand Island site represents a significant milestone in…

August 4, 2022

CGT Catapult joins personalized cell therapy consortium

by

Cell and Gene Therapy Catapult (CGT Catapult) has launched a consortium to advance manufacturing of personalized cell therapies. The consortium, of which UK-based advanced therapy developer Achilles Therapeutics is project coordinator, has been awarded $4.2 million by Horizon Europe to advance a bioprocessing manufacturing platform for personalized therapies. According to CGT, the existing manufacturing platforms on the market are hindered in their ability to deliver sufficient real-time dating during production, which limits overall scalability and decision making. The company said…

August 4, 2022

Merck forks out $35m for Kelun-Biotech ADC deal

by

Merck & Co. has entered into a partnership and exclusive license agreement with Kelun-Biotech to develop an investigational antibody drug conjugate (ADC) to treat solid tumors. The deal, of which Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical) will receive an upfront payment of $35 million and has the potential to get further commercial payments totalling up to $901 million dependent on specific milestones. Earlier this year, Merck (known as MSD outside of North America) chose to exercise an option…

August 4, 2022